Letter

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

Received:
Accepted:
Published:

Abstract

Senescent cells (SCs) accumulate with age and after genotoxic stress, such as total-body irradiation (TBI)1,2,3,4,5,6. Clearance of SCs in a progeroid mouse model using a transgenic approach delays several age-associated disorders7, suggesting that SCs play a causative role in certain age-related pathologies. Thus, a 'senolytic' pharmacological agent that can selectively kill SCs holds promise for rejuvenating tissue stem cells and extending health span. To test this idea, we screened a collection of compounds and identified ABT263 (a specific inhibitor of the anti-apoptotic proteins BCL-2 and BCL-xL) as a potent senolytic drug. We show that ABT263 selectively kills SCs in culture in a cell type– and species-independent manner by inducing apoptosis. Oral administration of ABT263 to either sublethally irradiated or normally aged mice effectively depleted SCs, including senescent bone marrow hematopoietic stem cells (HSCs) and senescent muscle stem cells (MuSCs). Notably, this depletion mitigated TBI-induced premature aging of the hematopoietic system and rejuvenated the aged HSCs and MuSCs in normally aged mice. Our results demonstrate that selective clearance of SCs by a pharmacological agent is beneficial in part through its rejuvenation of aged tissue stem cells. Thus, senolytic drugs may represent a new class of radiation mitigators and anti-aging agents.

  • Subscribe to Nature Medicine for full access:

    $225

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    et al. Ionizing radiation–induced long-term expression of senescence markers in mice is independent of p53 and immune status. Aging Cell 9, 398–409 (2010).

  2. 2.

    & Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15, 482–496 (2014).

  3. 3.

    Ionizing radiation and aging: rejuvenating an old idea. Aging (Albany, NY) 1, 887–902 (2009).

  4. 4.

    et al. Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner. Blood 123, 3105–3115 (2014).

  5. 5.

    , , , & Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest. 123, 966–972 (2013).

  6. 6.

    The role of senescent cells in aging. Nature 509, 439–446 (2014).

  7. 7.

    et al. Clearance of p16Ink4a-positive senescent cells delays aging-associated disorders. Nature 479, 232–236 (2011).

  8. 8.

    et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644–658 (2015).

  9. 9.

    & The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961).

  10. 10.

    , , , & Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).

  11. 11.

    et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31, 722–733 (2014).

  12. 12.

    et al. Monitoring tumorigenesis and senescence in vivo with a p16INK4a-luciferase model. Cell 152, 340–351 (2013).

  13. 13.

    et al. p16INK4a reporter mice reveal age-promoting effects of environmental toxicants. J. Clin. Invest. 124, 169–173 (2014).

  14. 14.

    et al. Stem cell aging modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443, 421–426 (2006).

  15. 15.

    , , & The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118 (2010).

  16. 16.

    et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).

  17. 17.

    , , , & Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 8, 345–352 (2003).

  18. 18.

    & The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647–656 (2002).

  19. 19.

    , , & Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49–63 (2014).

  20. 20.

    , , , & Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 15, 1139–1153 (2014).

  21. 21.

    et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013).

  22. 22.

    et al. Structure-guided design of a selective Bcl-XL inhibitor. Nat. Chem. Biol. 9, 390–397 (2013).

  23. 23.

    , , & Stem cells and the aging hematopoietic system. Curr. Opin. Immunol. 22, 500–506 (2010).

  24. 24.

    , , , & Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. J. Exp. Med. 208, 2691–2703 (2011).

  25. 25.

    , & The aging hematopoietic stem cell compartment. Nat. Rev. Immunol. 13, 376–389 (2013).

  26. 26.

    , & Hematopoietic stem cell injury induced by ionizing radiation. Antioxid. Redox Signal. 20, 1447–1462 (2014).

  27. 27.

    , & Ionizing radiation and hematopoietic malignancies: altering the adaptive landscape. Cell Cycle 9, 3005–3011 (2010).

  28. 28.

    , & Regulation of hematopoietic stem cell aging in vivo by a distinct genetic element. Proc. Natl. Acad. Sci. USA 102, 5102–5107 (2005).

  29. 29.

    & Response of normal stem cells to ionizing radiation: a balance between homeostasis and genomic stability. Mutat. Res. 704, 167–174 (2010).

  30. 30.

    , & Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy. Anticancer Res. 5, 101–110 (1985).

  31. 31.

    in Hematopoiesis: Long-term Effects of Chemotherapy and Radiation (eds. Testa, N.G. & Gale, R.P.) 63–73 (Marcel Dekker, Inc., New York, 1988).

  32. 32.

    & in Hematopoiesis: Long-term Effects of Chemotherapy and Radiation (eds. Testa, N.G. & Gale, R.P.) 325–337 (Marcel Dekker, Inc., New York, 1988).

  33. 33.

    et al. Ionizing radiation-induced expression of Ink4a/Arf in murine bone marrow–derived stromal cell populations interferes with bone marrow homeostasis. Blood 119, 717–726 (2012).

  34. 34.

    , & The central role of muscle stem cells in regenerative failure with aging. Nat. Med. 21, 854–862 (2015).

  35. 35.

    et al. Phase 2 study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163–3169 (2012).

  36. 36.

    , , , & Aging biology and novel targets for drug discovery. J. Gerontol. A Biol. Sci. Med. Sci. 67, 168–174 (2012).

  37. 37.

    , & Preparation of mouse embryonic fibroblast cells suitable for culturing human embryonic and induced pluripotent stem cells. J. Vis. Exp. 64, 3854 (2012).

  38. 38.

    , , , & MicroRNA regulation of ionizing radiation–induced premature senescence. Int. J. Radiat. Oncol. Biol. Phys. 81, 839–848 (2011).

  39. 39.

    Probit Analysis (Cambridge University Press, Cambridge, UK, 1952).

  40. 40.

    , , & Protocols to detect senescence-associated β-galactosidase (SA–β-gal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 4, 1798–1806 (2009).

  41. 41.

    , & Inhibition of phosphatidylinostol 3-kinase uncouples H2O2-induced senescent phenotype and cell cycle arrest in normal human diploid fibroblasts. Exp. Cell Res. 298, 188–196 (2004).

  42. 42.

    , , , & Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 107, 358–366 (2006).

  43. 43.

    , , , & Short-term calorie restriction enhances skeletal muscle stem cell function. Cell Stem Cell 10, 515–519 (2012).

  44. 44.

    et al. Rejuvenation of the muscle stem cell population restores strength to injured aged muscles. Nat. Med. 20, 255–264 (2014).

Download references

Acknowledgements

We thank G. van Zant (University of Kentucky) for FBMD-1 stromal cells. This study was supported by the US National Institutes of Health (NIH) grants R01 CA122023 (D.Z.), R01 AI080421 (D.Z.), P20 GM109005 (M.H.-J. and D.Z.) and R37 AG009909 (J. Campisi); a grant from the Edward P. Evans Foundation (D.Z. and M.H.-J.); National Natural Science Foundation of China grant no. 81129020 (D.Z.); China National Program on Key Basic Research Project 2011CB964800-G (A.M.); and an Arkansas Research Alliance Scholarship from the Arkansas Science & Technology Authority (D.Z.).

Author information

Author notes

    • Jianhui Chang
    •  & Yingying Wang

    These authors contributed equally to this work.

Affiliations

  1. Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

    • Jianhui Chang
    • , Yingying Wang
    • , Lijian Shao
    • , Wei Feng
    • , Yi Luo
    • , Xiaoyan Wang
    • , Nukhet Aykin-Burns
    • , Kimberly Krager
    • , Martin Hauer-Jensen
    •  & Daohong Zhou
  2. Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

    • Jianhui Chang
    • , Yingying Wang
    • , Lijian Shao
    • , Wei Feng
    • , Yi Luo
    • , Xiaoyan Wang
    • , Nukhet Aykin-Burns
    • , Kimberly Krager
    • , Martin Hauer-Jensen
    •  & Daohong Zhou
  3. Institute of Radiation Medicine, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Tianjin, China.

    • Yingying Wang
    •  & Aimin Meng
  4. Buck Institute for Research on Aging, Novato, California, USA.

    • Remi-Martin Laberge
    • , Marco Demaria
    •  & Judith Campisi
  5. Lawrence Berkeley National Laboratory, Berkeley, California, USA.

    • Judith Campisi
  6. Department of Medicine and Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

    • Krishnamurthy Janakiraman
    •  & Norman E Sharpless
  7. Gladstone Institute of Cardiovascular Disease, San Francisco, California, USA.

    • Sheng Ding
  8. Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

    • Usha Ponnappan

Authors

  1. Search for Jianhui Chang in:

  2. Search for Yingying Wang in:

  3. Search for Lijian Shao in:

  4. Search for Remi-Martin Laberge in:

  5. Search for Marco Demaria in:

  6. Search for Judith Campisi in:

  7. Search for Krishnamurthy Janakiraman in:

  8. Search for Norman E Sharpless in:

  9. Search for Sheng Ding in:

  10. Search for Wei Feng in:

  11. Search for Yi Luo in:

  12. Search for Xiaoyan Wang in:

  13. Search for Nukhet Aykin-Burns in:

  14. Search for Kimberly Krager in:

  15. Search for Usha Ponnappan in:

  16. Search for Martin Hauer-Jensen in:

  17. Search for Aimin Meng in:

  18. Search for Daohong Zhou in:

Contributions

J. Chang and Y.W. designed, performed and analyzed most of the experiments; L.S., R.-M.L. and M.D. designed, performed and analyzed some experiments; W.F., Y.L., X.W., N.A.-B., K.K. and K.J. performed experiments; N.E.S. interpreted data and revised the manuscript; J. Campisi provided mice, designed the study, analyzed and interpreted data, and revised the manuscript; U.P. and M.H.-J. interpreted data and revised the manuscript; S.D. and A.M. designed the study, analyzed and interpreted data, and revised the manuscript; D.Z. conceived, designed and supervised the study, analyzed and interpreted data, and wrote the manuscript. All authors discussed the results and commented on the manuscript.

Competing interests

J. Chang, Y.W., L.S., W.F., Y.L., and D.Z. are inventors of a pending patent application for use of Bcl-2 and/or Bcl-xL inhibitors as anti-aging agents. J. Campisi and D.Z. are co-founders and advisors of Cenexys/Unity that develops senolytic drugs.

Corresponding author

Correspondence to Daohong Zhou.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–11 & Supplementary Tables 1–5